6亿！中国千亿药企，杀入AI制药！
Ranking
No observed public metrics; popularity remains neutral/archived.
Merged summary
TL;DR - China’s Sino Biopharmaceutical says it invested roughly RMB 600 million over three years to integrate AI across drug discovery, manufacturing, and commercialization. The effort matters because AI-designed candidates have reached clinical and regulatory milestones while manufacturing applications report meaningful yield and cost gains.
- AI-assisted development now spans six platforms, including small molecules, ADCs, siRNA, molecular glues, and targeted protein degradation.
- The AI-designed BCL-2 inhibitor TQB3909 has entered priority review after a marketing application; several OAPD-derived PROTAC candidates are in clinical trials.
- Deployed tools include protein-structure prediction, intelligence gathering, supply-chain optimization, and adverse-event report processing.
- AI-based process optimization reportedly increased PD-L1 antibody output by more than 20% and reduced biologics manufacturing costs by 20%.
Sources (1)
6亿！中国千亿药企，杀入AI制药！
TL;DR - China’s Sino Biopharmaceutical says it invested roughly RMB 600 million over three years to integrate AI across drug discovery, manufacturing, and commercialization. The effort matters because AI-designed candidates have reached clinical and regulatory milestones while manufacturing applications report meaningful yield and cost gains.
- AI-assisted development now spans six platforms, including small molecules, ADCs, siRNA, molecular glues, and targeted protein degradation.
- The AI-designed BCL-2 inhibitor TQB3909 has entered priority review after a marketing application; several OAPD-derived PROTAC candidates are in clinical trials.
- Deployed tools include protein-structure prediction, intelligence gathering, supply-chain optimization, and adverse-event report processing.
- AI-based process optimization reportedly increased PD-L1 antibody output by more than 20% and reduced biologics manufacturing costs by 20%.